In addition, trials using LTCC antagonists in bipolar disorder can (and should) now select or stratify participants based on CACNA1C risk genotype, as this may modify the treatment effect,31, 69 and in due course may allow pharmacogenetic prediction of response. Here, CACNA1C is linked to bipolar disorder.